LivaNova price target raised to $75 from $70 at Mizuho

Mizuho raised the firm’s price target on LivaNova to $75 from $70 and keeps a Buy rating on the shares. The company posted a Q4 beat, driven by outperformance in its cardiopulmonary segment despite a cybersecurity setback, the analyst tells investors in a research note. The firm says momentum is expected to continue into 2024 offset by manufacturing investments.